<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82513">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031146</url>
  </required_header>
  <id_info>
    <org_study_id>45122-A</org_study_id>
    <secondary_id>R01NS082120</secondary_id>
    <nct_id>NCT02031146</nct_id>
  </id_info>
  <brief_title>Lumbar Puncture and Syphilis Outcome</brief_title>
  <official_title>Lumbar Puncture and Syphilis Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treponema pallidum, the bacterium that causes syphilis, invades the central nervous system
      in about 40% of patients with syphilis. This happens early after infection. Patients with
      neuroinvasion are at risk of developing serious neurological complications, including vision
      or hearing loss, stroke and dementia. Because neuroinvasion can happen without symptoms, the
      only way to identify it is by performing a lumbar puncture (LP) to examine cerebrospinal
      fluid (CSF).The overall hypothesis to be tested in this study is that a strategy of
      immediate LP, followed by therapy based on CSF evaluation, results in better serological and
      functional outcomes in patients with syphilis who are at high risk for neuroinvasion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum RPR titer</measure>
    <time_frame>6-12 months</time_frame>
    <description>Decline in serum RPR titer by four-fold or to nonreactive at 6 months in early syphilis or at 12 months in late syphilis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>LP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants undergo lumbar puncture for CSF evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No LP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants do not undergo lumbar puncture and CSF is not examined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <arm_group_label>LP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 18 years or older

          2. Current syphilis defined as:

             Reactive serum Rapid Plasma Reagin (RPR) test and signs of primary or secondary
             syphilis;

             For individuals without clinical evidence of primary or secondary syphilis:

             â€¢ Reactive serum RPR test with a) no history of syphilis; or b) last recorded serum
             RPR or Venereal Diseases Research Laboratory (VDRL) test nonreactive; or c) a 4-fold
             increase in RPR titer relative to most recent lowest titer, and d) a reactive
             treponemal serological test if no previous reactive test

          3. Primary language is English or English is a second language but patient
             self-describes as fluent in English

          4. Able to provide informed consent

          5. If treated with benzathine penicillin G (BPG), it must have occurred less than 14
             days before the entry visit (before the first visit if there is more than one entry
             visit)

        Exclusion Criteria:

          1. Provider plans neurosyphilis (NS) treatment regardless of whether the patient has an
             lumbar puncture (LP)

          2. Receipt of antibiotic treatment that would be effective for NS (for example, IV or
             intramuscular (IM) beta-lactam antibiotics [other than BPG]) within one month before
             study entry; single dose of IM ceftriaxone in the last month is not exclusionary

          3. Allergy to penicillin or lidocaine

          4. Contraindication to LP, including untreatable coagulation disorder, use of
             anticoagulants that cannot be temporarily discontinued, thrombocytopenia, focal
             neurological examination

          5. Other known cause of central nervous system (CNS) infection in the last year,
             including that due to bacterial, fungal, protozoal or viral agents, such as
             tuberculosis, Cryptococcus, toxoplasmosis or herpes zoster that could confound
             interpretation of CSF results

          6. Unlikely to be able to comply with study requirements or complete the study, for
             example, planning to leave the area &lt; 6 months after enrollment

          7. Subjects will not be allowed to re-enroll in this study with a new episode of
             syphilis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Marra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina M Marra, MD</last_name>
    <phone>206-897-5400</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina M Marra, MD</last_name>
      <phone>206-394-9096</phone>
      <email>cmarra@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christina Marra</investigator_full_name>
    <investigator_title>Professor, Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
